How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines?

Archives of Medical Science

Volumn 8, Issue 4, 2012, Pages 608-613

  Mark, Laszlo ^a   Paragh, György ^b   Karadi, Istvan ^c   Reiber, Istvan ^d   Pados, Gyula ^e   Kiss, Zoltan ^f  

^a Pandy Kalman Bekes County Hospital   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d 4th Department of Medicine   (Hungary)

^e Szent Imre Hospital   (Hungary)

^f MSD Hungary Kft   (Hungary)

Author keywords

Hypercholesterolemia; LDL cholesterol; Prevention; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DYSLIPIDEMIA; EUROPE; FEMALE; GENERAL PRACTITIONER; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HUNGARY; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN; PRACTICE GUIDELINE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TREND STUDY;

EID: 84866884582     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.30283     Document Type: Article

References (27)

1. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' CTT Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170?000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
2. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009; 53: 316-22.
3. Chan DKY, O'Rourke F, Shen Q, Mark JCS, Hung WT. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand 2011; 124: 188-95.
4. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
5. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-64.
6. Hennekens CH, Drowos J. Statins: the high risks of discontinuation and large benefits of continuation. Arch Med Sci 2011; 7: 931-2.
7. Nissen SE, Tuczcu M, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80. (Pubitemid 38541684)
8. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 2006; 295: 1556-65.
9. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87.
10. Reiner Z, Catapano AL, De Backer G et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-818.
11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
12. Hermans MP, Cabezas MC, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010; 26: 445-54.
13. Katsiki N, Mikhailidis DP, Athyros VG, et al. Are we getting to lipid targets in real life? Arch Med Sci 2010; 6: 639-41.
14. Packard CJ. Benefits of lipid regulation in acute coronary syndrome. Arch Med Sci 2010; 6 (Suppl 1A): S76-S82.
15. Leiter LA, Lundman P, da Silva PM, et al. DYSIS investigators. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 1343-51.
16. Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol 2011; 107: 886-90.
17. Mark L, Paragh G, Karadi I, Reiber I, Pados G. Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008. Arch Med Sci 2010; 6: 695-700.
18. Mark L, Paragh G, Karadi I, Reiber I, Pados G, Kiss Z. An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the Plus Program. Arch Med Sci 2011; 7: 760-6.
19. The IV. Hungarian Cardiovascular Consensus Conference. Metabolizmus 2010; 8 Suppl A: 2-96.
20. Akram ON, Bernier A, Petrides F, et al. Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol 2010; 30: 1279-81.
21. Pandey S, Bissonnette S, Boukas S, et al. Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci 2011; 7: 767-75.
22. Mark L, Paragh G, Reiber I. The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients. The rosuvastatin monotherapy looks to be insufficient. Curr Med Res Opin 2011; 27: 1959-60.
23. Mark L, Reiber I, Bajnok L, Karadi I, Paragh G. The Effect of Switching to the High-Efficient Rosuvastatin on the Success of Lipid Lowering Therapy in High Risk Patients. The CORVUS (Controlled Targets for High Vascular Risk Patients Using Effective Statins) Study. Pharm Anal Acta 2012; S10: 001. doi:10.4172/2153-2435.S10-001.
24. Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Cardiovasc Prev Rehabil 2012; 19: 221-30.
25. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
26. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-186. (Pubitemid 46089734)
27. Jermendy G, Wittmann I, Nagy L, et al. Persistence of oral antidiabetic treatment among patients with type 2 diabetes in Hungary, 2007-2008. Metabolizmus 2011; 9: 21-7.